Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhenju Jiangyapian
- Development stage
- Unknown
- Lead developer
- Huabao Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zhenju Jiangyapian is an approved oral antihypertensive combination drug developed and manufactured by Huabao Pharmaceutical (Suzhou Huabao Pharmaceutical). It is a hybrid formulation that combines Traditional Chinese Medicine (TCM) ingredients with conventional Western pharmaceuticals. The standard formulation typically includes extracts of wild chrysanthemum (Flos Chrysanthemi Indici) and pearl powder (Concha Margaritifera Usta) alongside the flavonoid rutin, the diuretic hydrochlorothiazide, and the alpha-2 adrenergic agonist clonidine hydrochloride. It is indicated for the treatment of hypertension. While the TCM components are intended to clear heat and calm the liver according to traditional theory, the primary pharmacological blood-pressure-lowering effects are driven by the inhibition of the sodium-chloride symporter in the kidneys and the activation of central alpha-2 receptors.
- Brand names
- Zhenju Jiangyapian
- Other names
- 珍菊降压片
02
Targets
ADRA2A (α2A)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)
Beyond the preview
Go deeper on Zhenju Jiangyapian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhenju Jiangyapian.